Rhinosinusitis is Suffering.

However,

the diagnosis and treatment of Rhinosinusitis
remain inadequate.

Recent studies revealed that GZMK is a pivotal inflammatory enzyme driving the initiation and progression of rhinosinusitis.

By activating the complement cascade, GZMK amplifies inflammation, emerging as a promising therapeutic target for precision intervention.

Meanwhile, its early elevation and strong correlation with disease onset highlight its potential as an early diagnostic biomarker.

Based on this, we bring ...

Based on this, we bring DOCTOR

Rapid Test Strip

Given that GZMK is a more sensitive and specific biomarker for rhinosinusitis, we developed a colloidal gold test strip for its early-stage detection.

First-ever computer-designed binder test strip
Novel dual-binder sandwich assay
5-minute rapid home test
Accessible binders replacing antibodies

Drug Candidate

Drug screening discovered Nafamostat mesylate, an FDA-approved drug that efficiently inhibits GZMK, providing a precise therapeutic strategy for rhinosinusitis.

Small-molecule inhibitor
IC50 = 195 nM demonstrates outstanding potency

Protein Design Tool Kit

We designed an innovative one-shot protein design tool kit, achieving more efficient and precise design of high-affinity protein binders with limited experimental throughput.

High-throughput Screening Platform

We introduce a high-throughput screening platform. Built upon microfluidic chips, it is automated, integrated and cloud-visualized.

Let's Make the DOCTOR Real